Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Sorry, meant GDR.
ADVFN shows GDX had a trade of 1m after market closed.
If NCYT are struggling to meet their test targets, why don't they just buy GDR?
Looks like the virus is now affecting KNOS. Can't see anything positive happening till the lockdown is over and everyone is back to work.
I sold yesterday at 62p. The time to buy back will be just before the close, or tomorrow morning. Let the herd panic sell and have their stoplosses triggered.
NCYT has become expensive to buy at 500p. Shall be selling some to buy more here.
NXC
14 Apr '20 - 15:39 - 36 of 36
0 4 0
Well done to the team at GeneDrive - I am the former Chairman ( several years back) and my successor Ian Gilham and the CEO David Budd have done a great job of keeping the show on the road - in Gino Miele they have a brilliant R&D guy who is capable of delivering on a Covid19 test. GeneDrive has the absolute capability of delivering a decentralised MolecularDx test at the point of use and to get a result back within an hour if not shorter - it uses a simple nasal swab and one can be easily trained to carry out the test. If the UK Government had any sense they would view this as a strategic asset and ensure every care home, A&E dept and doctor's surgery had one and to go further that every workplace had one in the same way as you have a first aid box or a defibrilator and people were trained accordingly - if not for this pandemic then for the one just around the corner. GeneDrive is fundamentally undervalued and deserves to be re-rated. For avoidance of doubt I remain a long-term holder.
The country suffering the most from the virus is USA, so we may gat more buyers in at 2.30pm. Certainly looks like it is going much higher.
Without an rns, it will get hit by profit taking. Traders will move into GDR, which is still at 41p.
Coronavirus Test Development
With a rapid global shift of healthcare emphasis towards testing and treatment of COVID-19, the Company has refocussed a significant part of its core resources towards development of two SARS-COV-2 tests.
The Company’s first assay, already in development, is an instrument-agnostic molecular assay (the Genedrive® 96 SARS-COV-2 test) that can be performed on a variety of high throughput molecular testing platforms already installed in many laboratories around the world. The test will determine if a patient has an active SARS-COV-2 infection. The Company anticipates that a clinically validated high throughput test format could be available in approximately eight weeks.
The Genedrive®96 SARS-COV-2 test is designed as a one-step, ready-to-go freeze dried assay. Based on discussions with sizable third party suppliers the Company expects it could have the ability to ramp quickly to high production volumes of over 10,000 tests per hour, and thus this could be both a material revenue generator for the Company and significant contributor to addressing the global pandemic. Freeze dried assays require no refrigeration and are stable in transport, which is a significant logistical advantage for rapid shipment and global distribution.
A second test will also be developed by the Company where it will adapt its formulations to run on the Genedrive® instrument platform to provide a rapid point-of-care SARS-COV-2 test to allow testing outside of the main hospital environment in places such as clinics, intensive care units, or where rapid and accurate testing for SARS-COV-2 might be required. The rationale for the two-stage development is that the testing, logistics, validation, and trial work to provide testing on a turnkey instrument system like Genedrive® takes additional time compared to an agnostic assay format.
The Company believes that the principal risks on SARS-COV-2 assays development are related to business continuity and supply chain robustness for raw materials in the market, as opposed to technical challenges. The Company is also actively seeking development partners, distributors and non-dilutive funding to support the most rapid development possible.
In S.Korea they now have increasing numbers of people catching the virus for the second time. This means more testing and more money for those companies involved in this field.
GDR market cap £14m. NCYT £255m
That's because the profits from NCYT is coming here.
You mean GDR. This is about to start going mental also.
One of their fortes is their customer service. Always get a reply to all my emails.
You could go on twitter and everywhere their goods are advertised, and say what you think under the advert. It is easy to make a brand unfashionable.
Price rise seems to have been caused by Brexit being finalized. A lot of NHS contracts were suspended due to Brexit uncertainty; some of these contracts will now be allocated to Knos. Happy days!
What a great performance today. Decent volume also.